AKT1 and Hyperglycemia: Together with canonical kinase-based activation, this ATP-dependent mechanism supports a dual regulatory model of PI3K/AKT signaling, offering novel insights into hyperglycemia-induced resistance to PI3K inhibitors,44 and underscores the clinical potential of combined PI3K and glycolysis-targeted therapies.